BMS-908662
- Generic Name
- BMS-908662
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C24H19ClN4O4
- CAS Number
- 870603-16-0
- Unique Ingredient Identifier
- DW2NWI3TFN
- Background
BMS-908662 has been used in trials studying the treatment of Melanoma and Colorectal Cancer.
- Associated Conditions
- -
- Associated Therapies
- -
Safety and Efficacy Study of BMS-908662 in Combination With Ipilimumab in Subjects With Advanced Melanoma
- First Posted Date
- 2010-11-22
- Last Posted Date
- 2013-06-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 8
- Registration Number
- NCT01245556
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
🇺🇸Jedd D. Wolchok, Md,Phd, New York, New York, United States
Safety and Efficacy Study of BMS-908662 Alone or in Combination With Cetuximab in Subjects With K-RAS or B-RAF Mutation Positive Advanced or Metastatic Colorectal Cancer
- First Posted Date
- 2010-03-15
- Last Posted Date
- 2016-06-27
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 17
- Registration Number
- NCT01086267
- Locations
- 🇺🇸
Oncology Research Associates D/B/A, Scottsdale, Arizona, United States
🇨🇦Local Institution, Ottawa, Ontario, Canada
🇺🇸Usc Norris Comprehensive Cancer Center, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath